Inside Precision Medicine March 26, 2025
Character Biosciences, a NJ-based ophthalmology-focused biotech, has raised $93 Million in Series B funding to develop precision medicine-based eye therapies for conditions such as age-related macular degeneration (AMD).
The company is using a data-driven approach to reclassify common diseases such as AMD into genetic subtypes so treatment can be more targeted and effective for patients.
The Series B round was co-led by Israel’s largest health tech venture capital fund, aMoon, as well as Luma group, a NY-based, health tech-focused investment firm. Other investors contributing to the round included Bausch + Lomb, Jefferson Life Sciences, Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures.
The company started life as Clover Therapeutics in 2019 but rebranded to Character Biosciences in 2022 when...
Today's Sponsors
Today's Sponsor